As many as eight of every 10 patients who received elecoglipron reached their guideline-recommended glycaemic targets, which we know are linked with better outcomes and long-term health. Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca said: Our ambition is to have a portfolio that can tackle many of the cardiovascular, renal and metabolic diseases that are leading causes of death worldwide
And so I think that they will continue to manufacture all the junk and the public, because theyre addicted, will continue to vote with their taste buds
A Platform for Multi-Indication Drug Development The broader implication is that GLP-1 therapeutics may represent a platform technology rather than a single-indication drug class
S3)):529
If youre going to use Dihexa anyway, this article walks through the dose ranges discussed, the timing patterns, what people report about cycling, and how to think about risk in the absence of validated guidance